

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

GB 0414126

GR-7/4126.

REC'D 13 OCT 2004
WIPO PCT

**Intyg
Certificate**

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) *Sökande* AstraZeneca AB, Södertälje SE
Applicant (s)

(21) *Patentansökningsnummer* 0302571-5
Patent application number

(86) *Ingivningsdatum* 2003-09-26
Date of filing

Stockholm, 2004-08-02

*För Patent- och registreringsverket
For the Patent- and Registration Office*

Hjördis Segerlund
Hjördis Segerlund

*Avgift
Fee* 170:-

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF

5 **BACKGROUND OF THE INVENTION**

1. Field of the invention

10 The invention is related to therapeutic compounds, pharmaceutical compositions containing these compounds, manufacturing processes thereof and uses thereof. Particularly, the present invention is related to compounds that may be effective in treating pain, cancer, multiple sclerosis, Parkinson's disease, cancer, Huntington's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and/or cardiovascular disorders.

15 2. Discussion of Relevant Technology

15 Pain management has been studied for many years. It is known that cannabinoid receptor (e.g., CB₁ receptor, CB₂ receptor) ligands including agonists, antagonists and inverse agonists produce relief of pain in a variety of animal models by interacting with CB₁ and/or CB₂ receptors. Generally, CB₁ receptors are located predominately in the central nervous system, whereas CB₂ receptors are located 20 primarily in the periphery and are primarily restricted to the cells and tissues derived from the immune system.

25 While CB₁ receptor agonists, such as Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and anadamide, are useful in anti-nociception models in animals, they tend to exert undesired CNS side-effects, e.g., psychoactive side effects, the abuse potential, drug dependence and tolerance, etc. These undesired side effects are known to be mediated by the CB₁ receptors located in CNS. There are lines of evidence, however, suggesting that CB₁ agonists acting at peripheral sites or with limited CNS exposure can manage pain in humans or animals with much improved overall in vivo profile.

30 Therefore, there is a need for new CB₁ receptor ligands such as agonists that may be useful in managing pain or treating other related symptoms or diseases with reduced or minimal undesirable CNS side-effects.

DESCRIPTION OF THE INVENTION

The present invention provides CB₁ receptor ligands which may be useful in treating pain and/or other related symptoms or diseases.

Definitions

5 Unless specified otherwise within this specification, the nomenclature used in this specification generally follows the examples and rules stated in *Nomenclature of Organic Chemistry, Sections A, B, C, D, E, F, and H*, Pergamon Press, Oxford, 1979, which is incorporated by reference herein for its exemplary chemical structure names and rules on naming chemical structures.

10 "CB₁/CB₂ receptors" means CB₁ and/or CB₂ receptors.

The term "C_{m-n}" or "C_{m-n} group" used alone or as a prefix, refers to any group having m to n carbon atoms.

The term "hydrocarbon" used alone or as a suffix or prefix, refers to any structure comprising only carbon and hydrogen atoms up to 14 carbon atoms.

15 The term "hydrocarbon radical" or "hydrocarbyl" used alone or as a suffix or prefix, refers to any structure as a result of removing one or more hydrogens from a hydrocarbon.

The term "alkyl" used alone or as a suffix or prefix, refers to monovalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms. Unless otherwise specified, "alkyl" generally includes both saturated alkyl and unsaturated alkyl.

20 The term "alkylene" used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serve to link two structures together.

25 The term "alkenyl" used alone or as suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 2 up to about 12 carbon atoms.

The term "alkynyl" used alone or as suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond and comprising at least 2 up to about 12 carbon atoms.

30 The term "cycloalkyl," used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms.

The term "cycloalkenyl" used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 3 up to about 12 carbon atoms.

5 The term "cycloalkynyl" used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon triple bond and comprising about 7 up to about 12 carbon atoms.

10 The term "aryl" used alone or as suffix or prefix, refers to a hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (e.g., $4n + 2$ delocalized electrons) and comprising 5 up to about 14 carbon atoms, wherein the radical is located on a carbon of the aromatic ring.

The term "non-aromatic group" or "non-aromatic" used alone, as suffix or as prefix, refers to a chemical group or radical that does not contain a ring having aromatic character (e.g., $4n + 2$ delocalized electrons).

15 The term "arylene" used alone or as suffix or prefix, refers to a divalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (e.g., $4n + 2$ delocalized electrons) and comprising 5 up to about 14 carbon atoms, which serves to link two structures together.

20 The term "heterocycle" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s). Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms therebetween. Heterocycle may have aromatic character or may not have aromatic character.

25 The term "heteroalkyl" used alone or as a suffix or prefix, refers to a radical formed as a result of replacing one or more carbon atom of an alkyl with one or more heteroatoms selected from N, O, P and S.

30 The term "heteroaromatic" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s), wherein the ring-

containing structure or molecule has an aromatic character (e.g., $4n + 2$ delocalized electrons).

The term "heterocyclic group," "heterocyclic moiety," "heterocyclic," or "heterocyclo" used alone or as a suffix or prefix, refers to a radical derived from a heterocycle by removing one or more hydrogens therefrom.

5 The term "heterocyclyl" used alone or as a suffix or prefix, refers a radical derived from a heterocycle by removing one hydrogen from a carbon of a ring of the heterocycle.

10 The term "heterocyclylene" used alone or as a suffix or prefix, refers to a divalent radical derived from a heterocycle by removing two hydrogens therefrom, which serves to links two structures together.

The term "heteroaryl" used alone or as a suffix or prefix, refers to a heterocyclyl having aromatic character, wherein the radical of the heterocyclyl is located on a carbon of an aromatic ring of the heterocyclyl.

15 The term "heterocylcoalkyl" used alone or as a suffix or prefix, refers to a heterocyclyl that does not have aromatic character.

The term "heteroarylene" used alone or as a suffix or prefix, refers to a heterocyclylene having aromatic character.

20 The term "heterocycloalkylene" used alone or as a suffix or prefix, refers to a heterocyclylene that does not have aromatic character.

The term "six-membered" used as prefix refers to a group having a ring that contains six ring atoms.

25 The term "five-membered" used as prefix refers to a group having a ring that contains five ring atoms.

A five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.

Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 30 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4- oxadiazolyl.

A six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.

Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.

The term "substituted" used as a prefix refers to a structure, molecule or group, wherein one or more hydrogens are replaced with one or more

5 C_{1-12} hydrocarbon groups, or one or more chemical groups containing one or more heteroatoms selected from N, O, S, F, Cl, Br, I, and P. Exemplary chemical groups containing one or more heteroatoms include heterocyclyl, $-NO_2$, $-OR$, $-Cl$, $-Br$, $-I$, $-F$, $-CF_3$, $-C(=O)R$, $-C(=O)OH$, $-NH_2$, $-SH$, $-NHR$, $-NR_2$, $-SR$, $-SO_3H$, $-SO_2R$, $-S(=O)R$, $-CN$, $-OH$, $-C(=O)OR$, $-C(=O)NR_2$, $-NRC(=O)R$, oxo ($=O$), imino ($=NR$), thio ($=S$),
10 and oximino ($=N-OR$), wherein each "R" is a C_{1-12} hydrocarbyl. For example, substituted phenyl may refer to nitrophenyl, pyridylphenyl, methoxyphenyl, chlorophenyl, aminophenyl, etc., wherein the nitro, pyridyl, methoxy, chloro, and amino groups may replace any suitable hydrogen on the phenyl ring.

15 The term "substituted" used as a suffix of a first structure, molecule or group, followed by one or more names of chemical groups refers to a second structure, molecule or group, which is a result of replacing one or more hydrogens of the first structure, molecule or group with the one or more named chemical groups. For example, a "phenyl substituted by nitro" refers to nitrophenyl.

20 The term "optionally substituted" refers to both groups, structures, or molecules that are substituted and those that are not substituted.

Heterocycle includes, for example, monocyclic heterocycles such as: aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, dioxolane, sulfolane 2,3-dihydrofuran, 2,5-dihydrofuran tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydro-pyridine, 25 piperazine, morpholine, thiomorpholine, pyran, thiopyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dihydropyridine, 1,4-dioxane, 1,3-dioxane, dioxane, homopiperidine, 2,3,4,7-tetrahydro-1*H*-azepine homopiperazine, 1,3-dioxepane, 4,7-dihydro-1,3-dioxepin, and hexamethylene oxide.

In addition, heterocycle includes aromatic heterocycles, for example, pyridine, 30 pyrazine, pyrimidine, pyridazine, thiophene, furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, 1,2,3-triazole, tetrazole, 1,2,3-thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4-triazole, 1,3,4-thiadiazole, and 1,3,4- oxadiazole.

Additionally, heterocycle encompass polycyclic heterocycles, for example, indole, indoline, isoindoline, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, 1,4-benzodioxan, coumarin, dihydrocoumarin, benzofuran, 2,3-dihydrobenzofuran, isobenzofuran, chromene, chroman, isochroman, xanthene, 5 phenoxathiin, thianthrene, indolizine, isoindole, indazole, purine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, phenanthridine, perimidine, phenanthroline, phenazine, phenothiazine, phenoazine, 1,2-benzisoxazole, benzothiophene, benzoxazole, benzthiazole, benzimidazole, benztriazole, thioxanthine, carbazole, carbofine, acridine, pyrolizidine, and 10 quinolizidine.

In addition to the polycyclic heterocycles described above, heterocycle includes polycyclic heterocycles wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidine, 15 diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2.2.1]heptane.

Heterocyclyl includes, for example, monocyclic heterocyclyls, such as: aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxétanyl, thietanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1,2,3,6-tetrahydro-20 pyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3-dihydropyranyl, tetrahydropyranyl, 1,4-dihydropyridinyl, 1,4-dioxanyl, 1,3-dioxanyl, dioxanyl, homopiperidinyl, 2,3,4,7-tetrahydro-1*H*-azepinyl, homopiperazinyl, 1,3-dioxepanyl, 4,7-dihydro-1,3-dioxepinyl, and hexamethylene oxidyl.

In addition, heterocyclyl includes aromatic heterocycls or heteroaryl, for example, 25 pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4 oxadiazolyl.

Additionally, heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indolinyl, isoindolinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1,4-benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl, isochromanyl,

xanthenyl, phenoxythiinyl, thianthrenyl, indolizinyl, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, phenanthridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxazinyl, 1,2-benzisoxazolyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, 5 benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrolizidinyl, and quinolizidinyl.

In addition to the polycyclic heterocycls described above, heterocycl includes polycyclic heterocycls wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms 10 common to both rings. Examples of such bridged heterocycles include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl.

The term "alkoxy" used alone or as a suffix or prefix, refers to radicals of the general formula -O-R, wherein -R is selected from a hydrocarbon radical. Exemplary alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, 15 cyclopropylmethoxy, allyloxy, and propargyloxy.

The term "aryloxy" used alone or as suffix or prefix, refers to radicals of the general formula -O-Ar, wherein -Ar is an aryl.

The term "heteroaryloxy" used alone or as suffix or prefix, refers to radicals of the general formula -O-Ar', wherein -Ar' is a heteroaryl.

20 The term "amine" or "amino" used alone or as a suffix or prefix, refers to radicals of the general formula -NRR', wherein R and R' are independently selected from hydrogen or a hydrocarbon radical.

"Acyl" used alone, as a prefix or suffix, means -C(=O)-R, wherein -R is an 25 optionally substituted hydrocarbyl, hydrogen, amino or alkoxy. Acyl groups include, for example, acetyl, propionyl, benzoyl, phenyl acetyl, carboethoxy, and dimethylcarbamoyl.

Halogen includes fluorine, chlorine, bromine and iodine.

"Halogenated," used as a prefix of a group, means one or more hydrogens on the group is replaced with one or more halogens.

30 "RT" or "rt" means room temperature.

A first ring group being "fused" with a second ring group means the first ring and the second ring share at least two atoms therebetween.

"Link," "linked," or "linking," unless otherwise specified, means covalently linked or bonded.


5 When a first group, structure, or atom is "directly connected" to a second group, structure or atom, at least one atom of the first group, structure or atom forms a chemical bond with at least one atom of the second group, structure or atom.

"Saturated carbon" means a carbon atom in a structure, molecule or group wherein all the bonds connected to this carbon atom are single bond. In other words, there is no double or triple bonds connected to this carbon atom and this carbon atom generally adopts an sp^3 atomic orbital hybridization.

10 "Unsaturated carbon" means a carbon atom in a structure, molecule or group wherein at least one bond connected to this carbon atom is not a single bond. In other words, there is at least one double or triple bond connected to this carbon atom and this carbon atom generally adopts a sp or sp^2 atomic orbital hybridization.

15 Description of Preferred Embodiments

In one aspect, the invention provides a compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:



20

I

wherein

R^1 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{4-8} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, and C_{3-6} heterocycloalkyl, wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{4-8} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, and C_{3-6} heterocycloalkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6} alkylamino and di C_{1-6} alkylamino;

R^2 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, and C_{4-8} cycloalkenyl- C_{1-4} alkyl, wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, and C_{4-8} cycloalkenyl- C_{1-4} alkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, 5 methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6} alkylamino and diC_{1-6} alkylamino;

R^3 is selected from -H, C_{1-6} alkyl, C_{2-6} alkenyl, and C_{1-6} acyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{1-6} acyl used in defining R^3 is optionally substituted with one or more groups selected from $CH_3C(=O)-O-$, halogen, cyano, methoxy, ethoxy, 10 hydroxy, amino, alkylamino, dialkylamino, and C_{3-6} heterocycloalkyl; and R^4 is selected from -H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl.

Particularly, the compounds of the present invention are those of formula I, 15 wherein

R^1 is selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl- C_{1-4} alkyl and C_{3-6} heterocycloalkyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl- C_{1-4} alkyl and C_{3-6} heterocycloalkyl- C_{1-4} alkyl used in defining R^1 is optionally substituted by one or 20 more groups selected from halogen, methoxy, ethoxy, methyl, hydroxy, amino, C_{1-6} alkylamino and diC_{1-6} alkylamino;

R^2 is selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, and C_{4-6} cycloalkenyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, and C_{4-6} cycloalkenyl- C_{1-4} alkyl used in defining 25 R^2 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy and hydroxy;

R^3 is selected from -H, C_{1-6} alkyl, C_{2-6} alkenyl, and C_{1-6} acyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{1-6} acyl used in defining R^3 is optionally substituted with one or more groups selected from $CH_3C(=O)-O-$, halogen, methoxy, ethoxy, hydroxy, 30 amino, methylamino, dimethylamino, and C_{3-6} heterocycloalkyl; and R^4 is selected from -H and C_{1-3} alkyl.

More particularly, the compounds of the present invention are those of formula I,

5 wherein R¹ is selected from cyclopentyl-methyl, cyclohexyl-methyl, cyclobutyl-methyl, tetrahydropyranyl-methyl, tetrahydrofuranyl-methyl, morpholinyl-methyl, piperdinylethyl, N-methyl-piperdinylmethyl, and piperdanyl-methyl;

10 R² is selected from t-butyl, n-butyl, 2-methyl-2-butyl, isopentyl, 2-methoxy-2-propyl, 2-hydroxy-propyl, 1-methyl-propyl, 1,1-dimethyl-propyl, 1,1-dimethyl-3-buten-1-yl, ethyl, and 2-propyl;

15 R³ is selected from -H, C₁₋₆alkyl, and C₁₋₆acyl, wherein said C₁₋₆alkyl, and C₁₋₆acyl used in defining R³ is optionally substituted with one or more groups selected from CH₃C(=O)-O-, halogen, methoxy, hydroxy, amino, methylamino, dimethylamino, pyrrolidinyl, and morpholinyl; and

20 R⁴ is selected from -H and methyl.

25 Most particularly, the compounds of the present invention are those of formula I, wherein

25 R¹ is cyclohexyl-methyl and tetrahydropyranyl-methyl;

30 R² is t-butyl;

35 R³ is selected from -H, methyl, ethyl, propyl, 2-propyl, formyl, acetyl, ethylcarbonyl, 2-propylcarbonyl, t-butylcarbonyl, 2-amino-acetyl, 2-dimethylamino-acetyl, 2-acetoxy-acetyl, 2-hydroxy-acetyl, 2-bromo-acetyl, 2-(morpholin-1-yl)-acetyl, and 2-(pyrrolidin-1-yl)-acetyl; and

40 R⁴ is selected from -H and methyl.

45 It will be understood that when compounds of the present invention contain one or more chiral centers, the compounds of the invention may exist in, and be isolated as, enantiomeric or diastereomeric forms, or as a racemic mixture. The present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of Formula I. The optically active forms of the compound of the invention may be prepared, for example, by chiral chromatographic separation of a racemate, by synthesis from optically active starting materials or by asymmetric synthesis based on the procedures described thereafter.

It will also be appreciated that certain compounds of the present invention may exist as geometrical isomers, for example E and Z isomers of alkenes. The present invention includes any geometrical isomer of a compound of Formula I. It will further be understood that the present invention encompasses tautomers of the 5 compounds of the formula I.

It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compounds of the formula I.

10 Within the scope of the invention are also salts of the compounds of the formula I. Generally, pharmaceutically acceptable salts of compounds of the present invention may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example, HCl or acetic acid, to afford a physiologically acceptable 15 anion. It may also be possible to make a corresponding alkali metal (such as sodium, potassium, or lithium) or an alkaline earth metal (such as a calcium) salt by treating a compound of the present invention having a suitably acidic proton, such as a carboxylic acid or a phenol with one equivalent of an alkali metal or alkaline earth metal hydroxide or alkoxide (such as the ethoxide or methoxide), or a suitably basic 20 organic amine (such as choline or meglumine) in an aqueous medium, followed by conventional purification techniques.

In one embodiment, the compound of formula I above may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, 25 tartrate, citrate, methanesulphonate or *p*-toluenesulphonate.

We have now found that the compounds of the invention have activity as pharmaceuticals, in particular as modulators or ligands such as agonists, partial agonists, inverse agonist or antagonists of CB1 receptors. More particularly, the compounds of the invention exhibit selective activity as agonist of the CB1 receptors 30 and are useful in therapy, especially for relief of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive. Additionally, compounds of the present invention are useful in other

disease states in which dysfunction of CB1 receptors is present or implicated.

Furthermore, the compounds of the invention may be used to treat cancer, multiple sclerosis, Parkinson's disease, cancer, Huntington's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and cardiavascular disorders.

5 Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents.

10 Compounds of the invention are useful in disease states where degeneration or dysfunction of cannabinoid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET).

15 Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety and stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary incontinence, premature ejaculation, various mental illnesses, cough, lung oedema, various gastro-intestinal disorders; e.g. constipation, functional gastrointestinal disorders such as Irritable Bowel Syndrome and Functional
20 Dyspepsia, Parkinson's disease and other motor disorders, traumatic brain injury, stroke, cardioprotection following myocardial infarction, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.

25 Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care. Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.

30 Also within the scope of the invention is the use of any of the compounds according to the formula I above, for the manufacture of a medicament for the treatment of any of the conditions discussed above.

A further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the formula I above, is administered to a patient in need of such treatment.

5 Thus, the invention provides a compound of formula I, or pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

In a further aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

10 In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The term "therapeutic" and "therapeutically" should be construed accordingly. The term "therapy" within the context of the present invention further encompasses to administer an effective amount of a compound of the present invention, to mitigate 15 either a pre-existing disease state, acute or chronic, or a recurring condition. This definition also encompasses prophylactic therapies for prevention of recurring conditions and continued therapy for chronic disorders.

20 The compounds of the present invention are useful in therapy, especially for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.

25 In use for therapy in a warm-blooded animal such as a human, the compound of the invention may be administered in the form of a conventional pharmaceutical composition by any route including orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.

30 In one embodiment of the invention, the route of administration may be oral, intravenous or intramuscular.

The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level at the most appropriate for a particular patient.

For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid and liquid.

Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.

A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or table 5 disintegrating agents; it can also be an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided compound of the invention, or the active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

10 For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized moulds and allowed to cool and solidify.

15 Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.

The term composition is also intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is 20 thus in association with it. Similarly, cachets are included.

Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

Liquid form compositions include solutions, suspensions, and emulsions. For example, sterile water or water propylene glycol solutions of the active compounds 25 may be liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by 30 dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium

carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.

Depending on the mode of administration, the pharmaceutical composition will preferably include from 0.05% to 99%w (per cent by weight), more preferably from 0.10 to 50%w, of the compound of the invention, all percentages by weight being based on total composition.

A therapeutically effective amount for the practice of the present invention may be determined, by the use of known criteria including the age, weight and response of the individual patient, and interpreted within the context of the disease which is being treated or which is being prevented, by one of ordinary skills in the art.

Within the scope of the invention is the use of any compound of formula I as defined above for the manufacture of a medicament.

Also within the scope of the invention is the use of any compound of formula I for the manufacture of a medicament for the therapy of pain.

Additionally provided is the use of any compound according to Formula I for the manufacture of a medicament for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.

A further aspect of the invention is a method for therapy of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the formula I above, is administered to a patient in need of such therapy.


Additionally, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

Particularly, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier for therapy, more particularly for therapy of pain.

Further, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier use in any of the conditions discussed above.

In a further aspect, the present invention provides a method of preparing the compounds of the present invention.


In one embodiment, the invention provides a process for preparing a compound of formula I,



5

I

comprising the step of reacting a compound of formula II,

II

10 with a compound of R^2COX , in the presence of a base, such as an alkylamine, and optionally a coupling reagent, such as HATU, EDC, followed by treatment with an acid, such as HCl, acetic acid;

wherein

X is selected from Cl, Br, F and OH;

15 R^1 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{4-8} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, and C_{3-6} heterocycloalkyl, wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{4-8} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, and C_{3-6} heterocycloalkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6} alkylamino and di C_{1-6} alkylamino;

20 R^2 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, and C_{4-8} cycloalkenyl- C_{1-4} alkyl, wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, and C_{4-8} cycloalkenyl- C_{1-4} alkyl used in

defining R^2 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, and amino;

R^3 is selected from -H, C_{1-6} alkyl and C_{1-6} acyl optionally substituted with one or more groups selected from $CH_3C(=O)-O-$, halogen, cyano, methoxy, ethoxy,

5 hydroxy, amino, alkylamino, dialkylamino, and C_{3-6} heterocycloalkyl; and

R^4 is selected from -H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl.

Particularly, the present invention provides a method of preparing a compound
10 of formula I,

X is selected from Cl, Br, F and OH;

R^1 is selected from cyclopentyl-methyl, cyclohexyl-methyl, cyclobutyl-methyl, tetrahydropyranyl-methyl, tetrahydrofuranyl-methyl, morpholinyl-methyl, piperdinylethyl, N-methyl-piperdinylmethyl, and piperdanyl-methyl;

15 R^2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl, isopentyl, 2-methoxy-2-propyl, 2-hydroxy-propyl, 1-methyl-propyl, 1,1-dimethyl-propyl, 1,1-dimethyl-3-buten-1-yl, ethyl, and 2-propyl;

R^3 is selected from C_{1-6} alkyl and C_{1-6} acyl optionally substituted with one or more groups selected from $CH_3C(=O)-O-$, halogen, methoxy, hydroxy, amino,

20 methylamino, dimethylamino, pyrrolidinyl, and morpholinyl; and

R^4 is selected from -H and methyl.


Compounds of the present invention may also be prepared according to the synthetic routes as depicted in Schemes 1-4.

25

30


101194-1

Scheme 1




R^1 , R^2 , R^3 , and R^4 are as defined in the specifications.
Ar is phenylene.

Scheme 2




R^1 , R^2 , and R^4 are as defined in the specifications;
 R^7 and R^8 are optionally substituted C1-alkyl;
 Y and Z are halogen or -OH .
Ar is phenylene.

Scheme 3



$R^1, R^2, \text{ and } R^4$ are as defined in the specifications.
Ar is phenylene.
 R^5 is C_{1-6} alkyl.

Scheme 4



$R^1, R^2, \text{ and } R^4$ are as defined in the specifications.
 R^5, R^6 are $-\text{H}$ or C_{1-6} alkyl,
and Ar is phenylene.

5 Biological Evaluation

hCB₁ and hCB₂ receptor binding

Human CB₁ receptor from Receptor Biology (hCB1) or human CB₂ receptor from BioSignal (hCB2) membranes are thawed at 37 °C, passed 3 times through a 25-gauge blunt-end needle, diluted in the cannabinoid binding buffer (50 mM Tris, 2.5 mM EDTA, 5 mM MgCl₂, and 0.5 mg/mL BSA fatty acid free, pH 7.4) and aliquots containing the appropriate amount of protein are distributed in 96-well plates. The IC₅₀ of the compounds of the invention at hCB₁ and hCB₂ are evaluated from 10-point dose-response curves done with ³H-CP55,940 at 20000 to 25000 dpm per well (0.17-0.21 nM) in a final volume of 300 μl . The total and non-specific binding are determined in the absence and presence of 0.2 μM of HU210 respectively. The plates are vortexed and incubated for 60 minutes at room temperature, filtered through Unifilters GF/B (presoaked in 0.1% polyethyleneimine) with the Tomtec or Packard

harvester using 3 mL of wash buffer (50 mM Tris, 5 mM MgCl₂, 0.5 mg BSA pH 7.0). The filters are dried for 1 hour at 55 °C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μ l/well of MS-20 scintillation liquid.

5 hCB₁ and hCB₂ GTP γ S binding

Human CB₁ receptor from Receptor Biology (hCB1) or human CB₂ receptor membranes (BioSignal) are thawed at 37 °C, passed 3 times through a 25-gauge blunt-end needle and diluted in the GTP γ S binding buffer (50 mM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl₂, pH 7.4, 0.1% BSA). The EC₅₀ and E_{max} of the compounds of the invention are evaluated from 10-point dose-response curves done in 300 μ l with the appropriate amount of membrane protein and 100000-130000 dpm of GTPg³⁵S per well (0.11 –0.14 nM). The basal and maximal stimulated binding is determined in absence and presence of 1 μ M (hCB₂) or 10 μ M (hCB₁) Win 55,212-2 respectively. The membranes are pre-incubated for 5 minutes with 56.25 μ M (hCB₂) or 112.5 μ M (hCB₁) GDP prior to distribution in plates (15 μ M (hCB₂) or 30 μ M (hCB₁) GDP final). The plates are vortexed and incubated for 60 minutes at room temperature, filtered on Unifilters GF/B (presoaked in water) with the Tomtec or Packard harvester using 3 ml of wash buffer (50 mM Tris, 5 mM MgCl₂, 50 mM NaCl, pH 7.0). The filters are dried for 1 hour at 55 °C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μ l/well of MS-20 scintillation liquid. Antagonist reversal studies are done in the same way except that (a) an agonist dose-response curve is done in the presence of a constant concentration of antagonist, or (b) an antagonist dose-response curve is done in the presence of a constant concentration of agonist.

25 Based on the above assays, the dissociation constant (Ki) for a particular compound of the invention towards a particular receptor is determined using the following equation:

$$Ki = IC_{50}/(1+[rad]/Kd),$$

Wherein IC₅₀ is the concentration of the compound of the invention at which 30 50% displacement has been observed;

[rad] is a standard or reference radioactive ligand concentration at that moment; and

K_d is the dissociation constant of the radioactive ligand towards the particular receptor.

Using the above-mentioned assays, the K_i towards human CB_1 receptors for most compounds of the invention is measured to be in the range of 0.72-214 nM. The K_i towards human CB_2 receptors for most compounds of the invention is measured to be in the range of about 0.36-24.7 nM. The EC_{50} towards human CB_1 receptors for most compounds of the invention is measured to be in the range of about 0.85-176 nM. The E_{max} towards human CB_1 receptors for most compounds of the invention is measured to be in the range of about 60-131%.

10 In a particular embodiment, the K_i towards human CB_1 receptors for most compounds of the invention is measured to be in the range of 0.72-15 nM. The K_i towards human CB_2 receptors for most compounds of the invention is measured to be in the range of about 0.36- 3 nM. The EC_{50} towards human CB_1 receptors for most compounds of the invention is measured to be in the range of about 0.85-25 nM. The E_{max} towards human CB_1 receptors for most compounds of the invention is measured to be in the range of about 85-131%.


15

EXAMPLES

20 The invention will further be described in more detail by the following Examples which describe methods whereby compounds of the present invention may be prepared, purified, analyzed and biologically tested, and which are not to be construed as limiting the invention.

25 **Example 1**

N-(4-{{[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl) acetamide



2-*tert*-Butyl-1-(cyclohexylmethyl)-*N*-methyl-1*H*-benzimidazol-5-amine (40 mg, 0.133 mmol) (for preparation, see the following steps B, C, D, E and F) and 4-acetamidobenzene sulfonyl chloride (37 mg, 0.160 mmol) were stirred in 3 mL of dichloromethane containing a catalytic amount of DMAP overnight at rt. The solvent 5 was evaporated. The product was purified by reversed-phase HPLC using 20-80% CH₃CN/H₂O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 63 mg (78%); ¹H NMR (400 MHz, METHANOL-D₄) δ 1.21 (m, 5 H), 1.61 (m, 3 H), 1.64 (s, 9 H), 1.67 (m, 1 H), 1.75 (m, 2 H), 2.07 (m, 1 H), 2.11 (s, 3 H), 3.22 (s, 3 H), 4.42 (d, J=7.62 Hz, 2 H), 7.29 (dd, J=9.08, 2.05 Hz, 1 H), 7.42 (d, 10 J=8.98 Hz, 2 H), 7.50 (d, J=1.56 Hz, 1 H), 7.68 (d, J=8.98 Hz, 2 H), 7.82 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 497.2; Anal. Calcd for C₂₇H₃₆N₄O₃S + 1.4 TFA + 0.4 H₂O: C, 53.94; H, 5.80; N, 8.44. Found: C, 53.98; H, 5.79; N, 8.50.

Step B. Methyl (4-fluoro-3-nitrophenyl)carbamate



15

Methyl chloroformate (13.2 mL, 170.2 mmol) was added dropwise to a cold (0°C) dichloromethane (200 mL) solution of 4-fluoro-3-nitro aniline (24.15 g, 154.7 mmol) and DIPEA (35 mL, 201 mmol). The reaction mixture was stirred at rt overnight. The solution was then diluted with 200 mL of dichloromethane and washed with 2M 20 HCl, brine and dried over anhydrous MgSO₄. The solvent was concentrated and the product was directly used for next step without further purification. Yield: 35.5 g (99%); ¹H NMR (400 MHz, CHLOROFORM-D) δ 3.81 (s, 3 H), 7.02 (s, 1 H), 7.23 (m, 1 H), 7.72 (d, J=8.59 Hz, 1 H), 8.17 (dd, J=6.35, 2.64 Hz, 1 H).


25 **Step C. Methyl {4-[(cyclohexylmethyl)amino]-3-nitrophenyl}carbamate**



Methyl (4-fluoro-3-nitrophenyl)carbamate (1.00 g, 4.67 mmol) and cyclohexylmethyl amine (0.730 mL, 5.60 mmol) were stirred in EtOH (20 mL) containing TEA (1.0 mL, 7.00 mmol) at 75°C for 24h. The solvent was concentrated. The residue was dissolved in EtOAc and washed with 5% KHSO₄ solution, saturated NaHCO₃

5 solution, brine and dried over anhydrous MgSO₄. The crude product was purified by flash chromatography using 4:1/hex:EtOAc on silica gel. Yield: 1.05 g (73%); ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.04 (ddd, J = 24.02, 12.11, 2.93 Hz, 2H), 1.25 (m, 3H), 1.69 (m, 2H), 1.76 (m, 1H), 1.79 (m, 1H), 1.83 (m, 1H), 1.86 (m, 1H), 3.14 (dd, J = 6.44, 5.66 Hz, 2H), 3.78 (s, 3H), 6.46 (m, 1H), 6.84 (d, J = 9.37 Hz, 1H),
10 7.63 (m, 1H), 8.05 (d, J = 2.54 Hz, 1H), 8.09 (m, 1H).


Step D. Methyl {3-amino-4-[(cyclohexylmethyl)amino]phenyl}carbamate



Methyl {4-[(cyclohexylmethyl)amino]-3-nitrophenyl}carbamate (1.05 g, 3.42 mmol)
15 was dissolved in 30 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken in a Parr hydrogenation apparatus under H₂ atmosphere (40 psi) at rt overnight. The solution was filtered through Celite and the solvent was evaporated. The product was directly used for the next step without further purification. Yield: 950 mg (99%); MS (ESI) (M+H)⁺ 277.9.


20

Step E. Methyl [2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]carbamate



Methyl {3-amino-4-[(cyclohexylmethyl)amino]phenyl}carbamate (950 mg, 3.43 mmol) and DMAP (100 mg, 0.858 mmol) were dissolved in 25 mL of dichloromethane. Trimethylacetyl chloride (0.460 mL, 3.77 mmol) was added dropwise and the solution was stirred at rt for 1h. The solvent was concentrated. The residue was divided in two portions and each of them dissolved in 3 mL of glacial AcOH in a sealed tube. The solutions were heated at 150°C using a Personal Chemistry Smith Synthesizer microwave instrument for three intervals of 30 min (3 X 30 min). The two tubes were combined and the solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The crude product was purified by flash chromatography using 3:1/dichloromethane:diethyl ether. Yield: 656 mg (56%); ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.08 (m, 2H), 1.18 (m, 3H), 1.54 (s, 9H), 1.65 (m, 1H), 1.69 (m, 2H), 1.73 (dd, J = 5.96, 3.22 Hz, 2H), 2.02 (m, 1H), 3.78 (s, 3H), 4.10 (d, J = 7.42 Hz, 2H), 6.64 (m, 1H), 7.25 (d, J = 8.79 Hz, 1H), 7.39 (m, 1H), 7.59 (d, J = 1.76 Hz, 1H).

Step F. 2-*tert*-Butyl-1-(cyclohexylmethyl)-N-methyl-1*H*-benzimidazol-5-amine




Methyl [2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]carbamate (650 mg, 1.89 mmol) was dissolved in 20 mL of THF at 0°C under nitrogen. 1M HCl/ether (2.65 mL, 2.65 mmol) was added dropwise and the solution stirred at 0°C for 15min. LiAlH₄ (360 mg, 9.45 mmol) was then slowly added and the solution was stirred at rt overnight. The reaction mixture was quenched at 0°C by addition of MeOH (5 mL) followed by water (10 mL). The solution was diluted with EtOAc and washed with saturated NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The solvent was evaporated and the product was used directly for Step A without further purification. Yield: 544 mg (96%). ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.08 (s, 2 H) 1.17 (m, 3 H) 1.54 (s, 9 H) 1.64 (m, 2 H) 1.67 (m, 2 H) 1.72 (m, 2 H) 2.02 (m, 1 H) 2.87 (s,

3 H) 4.06 (d, $J=7.62$ Hz, 2 H) 6.60 (dd, $J=8.69, 2.25$ Hz, 1 H) 7.00 (d, $J=1.76$ Hz, 1 H) 7.12 (d, $J=8.59$ Hz, 1 H).

5 **Example 2**

N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-4-nitrobenzenesulfonamide



10 Following the procedure for Step A in Example 1, using 2-*tert*-butyl-1-(cyclohexylmethyl)-*N*-methyl-1*H*-benzimidazol-5-amine (253 mg, 0.845 mmol) (prepared according to procedures in Example 1, Steps B-F), 4-nitrobenzenesulfonyl chloride (245 mg, 1.10 mmol) and DMAP (catalytic) in 20mL of DCM. The solution was washed with saturated NaHCO_3 aqueous solution, brine and dried over anhydrous MgSO_4 . The crude product was purified by flash chromatography on silica gel using 2:1 / hexanes:EtOAc as eluent to afford the title product. Yield: 380 mg (93%); ^1H NMR (400 MHz, CHLOROFORM-D) δ 1.09 (m, 2 H) 1.21 (m, 3 H) 1.54 (s, 9 H) 1.64 (m, 1 H) 1.67 (m, 1 H) 1.71 (m, 1 H) 1.76 (m, 2 H) 2.03 (m, 1 H) 3.27 (s, 3 H) 4.12 (d, $J=7.23$ Hz, 2 H) 7.18 (m, $J=8.98$ Hz, 2 H) 7.30 (d, $J=8.98$ Hz, 1 H) 7.77 (d, $J=9.18$ Hz, 2 H) 8.30 (d, $J=9.18$ Hz, 2 H).

15

20

Example 3

4-Amino-*N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide


101194-1



5 *N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-4-nitrobenzenesulfonamide (375mg, 0.774 mmol) (prepared according to the procedure in Example 2) was dissolved in 20 mL of EtOH containing a catalytic amount of 10% Pd/C. The solution was shaken in a Parr hydrogenation apparatus under H₂ atmosphere (40 psi) at rt for 3h. The solution was filtered through celite and the solvent was concentrated. Yield: 332 mg (94%); ¹H NMR (400 MHz, METHANOL-D₄) δ 1.22 (m, 6 H) 1.60 (m, 1 H) 1.64 (s, 9 H) 1.67 (m, 1 H) 1.75 (m, 2 H) 2.08 (m, 1 H) 3.17 (s, 3 H) 4.42 (d, J=7.42 Hz, 2 H) 6.56 (d, J=8.79 Hz, 2 H) 7.14 (d, J=8.79 Hz, 2 H) 7.32 (dd, J=8.98, 1.95 Hz, 1 H) 7.49 (d, J=1.95 Hz, 1 H) 7.81 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 455.0; Anal. Calcd for C₂₅H₃₄N₄O₂S + 1.5 TFA + 0.4 H₂O: C, 53.14; H, 5.78; N, 8.85. Found: C, 53.10; H, 5.67; N, 8.92.

15 **Example 4**

N-(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl)phenyl)propanamide




20 25 4-Amino-*N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide (50 mg, 0.110 mmol) and propionyl chloride (0.012 mL, 0.143 mmol) were stirred in 3 mL of DCM containing a catalytic amount of DMAP at rt for 12h. The solvent was concentrated and the crude product was purified by reversed-phase HPLC using 20-80% CH₃CN/H₂O and then lyophilized affording the

101194-1

title compound as the corresponding TFA salt. Yield: 68mg (99%); ^1H NMR (400 MHz, METHANOL-D₄) δ 1.16 (t, $J=7.62$ Hz, 3 H) 1.21 (m, 5 H) 1.60 (m, 2 H) 1.64 (s, 9 H) 1.67 (m, 1 H) 1.75 (m, 2 H) 2.07 (m, 1 H) 2.38 (q, $J=7.62$ Hz, 2 H) 3.22 (s, 3 H) 4.42 (d, $J=7.62$ Hz, 2 H) 7.29 (dd, $J=9.08, 2.05$ Hz, 1 H) 7.42 (d, $J=8.98$ Hz, 2 H) 7.49 (d, $J=1.76$ Hz, 1 H) 7.69 (d, $J=8.98$ Hz, 2 H) 7.81 (d, $J=8.98$ Hz, 1 H); MS (ESI) ($M+H$)⁺ 511.2; Anal. Calcd for C₂₈H₃₈N₄O₃S + 1.5 TFA + 0.2 H₂O: C, 54.33; H, 5.87; N, 8.18. Found: C, 54.32; H, 5.84; N, 8.25.

Example 5

10 *N*-(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-methylpropanamide




Following the procedure for Example 4, using 4-amino-N-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide (50 mg, 0.110 mmol), isobutyryl chloride (0.015 mL, 0.143 mmol) and a catalytic amount of DMAP in 3mL of DCM. Yield: 73mg (99%); ^1H NMR (400 MHz, METHANOL-D₄) δ 1.15 (d, $J=6.83$ Hz, 6 H) 1.21 (m, 5 H) 1.62 (m, 2 H) 1.64 (s, 9 H) 1.67 (m, 1 H) 1.75 (m, 2 H) 2.08 (m, 1 H) 2.61 (dt, $J=13.82, 6.86$ Hz, 1 H) 3.23 (s, 3 H) 4.42 (d, $J=7.62$ Hz, 2 H) 7.29 (dd, $J=8.98, 1.95$ Hz, 1 H) 7.42 (d, $J=8.98$ Hz, 2 H) 7.50 (d, $J=1.95$ Hz, 1 H) 7.71 (d, $J=8.98$ Hz, 2 H) 7.82 (d, $J=8.98$ Hz, 1 H); MS (ESI) ($M+H$)⁺ 525.3; Anal. Calcd for C₂₉H₄₀N₄O₃S + 1.7 TFA + 0.3 H₂O: C, 53.75; H, 5.89; N, 7.74. Found: C, 53.75; H, 5.87; N, 7.73.

25 **Example 6**

N-(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide

f01194-1



Following the procedure for Example 4, using 4-amino-N-[2-tert-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-N-methylbenzenesulfonamide (50 mg,

5 0.110 mmol), trimethylacetyl chloride (0.018 mL, 0.143 mmol) and a catalytic amount of DMAP in 3mL of DCM. Yield: 76mg (99%); ¹H NMR (400 MHz, METHANOL-D₄) δ 1.21 (m, 5 H) 1.26 (s, 9 H) 1.62 (m, 2 H) 1.64 (s, 9 H) 1.67 (m, 1 H) 1.75 (m, 2 H) 2.07 (m, 1 H) 3.23 (s, 3 H) 4.42 (d, J=7.62 Hz, 2 H) 7.29 (dd, J=9.08, 2.05 Hz, 1 H) 7.42 (d, J=8.98 Hz, 2 H) 7.49 (d, J=1.76 Hz, 1 H) 7.73 (d, J=8.98 Hz, 2 H) 7.82 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 539.2; Anal. Calcd for C₃₀H₄₂N₄O₃S + 1.4 TFA + 0.5 H₂O: C, 55.69; H, 6.33; N, 7.92. Found: C, 55.70; H, 6.31; N, 7.92.

Example 7

15 *N*-[2-tert-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-(ethylamino)-*N*-methylbenzenesulfonamide



4-Amino-N-[2-tert-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-

20 methylbenzenesulfonamide (55 mg, 0.121 mmol), cesium carbonate (78 mg, 0.242 mmol) and ethyl iodide (0.011 mL, 0.133mmol) were dissolved in 1 mL of DMF in a sealed tube flushed with nitrogen. The solution was heated at 125°C in a Personal Chemistry SmithSynthesizer microwave instrument for 10 min. Another 0.133 mmol (0.011 mL) of ethyl iodide was added and the solution was heated for another 10 min.

25 This procedure was then repeated 3 more times. The solvent was then concentrated.


The residue was dissolved in EtOAc and washed with saturated NaHCO₃ aqueous solution, brine and dried over anhydrous MgSO₄. The solvent was concentrated and the crude product was purified by reversed-phase HPLC using 20-80% CH₃CN/H₂O and then lyophilized affording the title compound as the corresponding TFA salt.

5 Yield: 39 mg (54%); ¹H NMR (400 MHz, METHANOL-D₄) δ 1.19 (t, J=7.23 Hz, 3 H) 1.23 (m, 5 H) 1.62 (m, 2 H) 1.64 (s, 9 H) 1.67 (m, 1 H) 1.75 (m, 2 H) 2.08 (m, 1 H) 3.10 (q, J=7.23 Hz, 2 H) 3.17 (s, 3 H) 4.43 (d, J=7.62 Hz, 2 H) 6.52 (d, J=8.98 Hz, 2 H) 7.18 (d, J=8.98 Hz, 2 H) 7.32 (dd, J=8.98, 1.95 Hz, 1 H) 7.51 (d, J=2.15 Hz, 1 H) 7.81 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 483.3; Anal. Calcd for C₂₇H₃₈N₄O₂S + 1.8 TFA: C, 53.43; H, 5.83; N, 8.14. Found: C, 53.51; H, 5.81; N, 8.13.

Example 8

N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-(formylamino)-*N*-methylbenzenesulfonamide

15




4-Amino-*N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide (45 mg, 0.099 mmol), was heated in 1 mL of formic acid in a sealed tube at 125°C for 15 min using a Personal Chemistry SmithSynthesizer microwave instrument. The solvent was concentrated and the product was purified by reversed-phase HPLC using 20-80% CH₃CN/H₂O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 61 mg (99%); ¹H NMR (400 MHz, METHANOL-D₄) δ 1.21 (m, 5 H), 1.62 (m, 2 H), 1.64 (s, 9 H), 1.67 (m, 1 H), 1.75 (m, 2 H), 2.08 (m, 1 H), 3.23 (s, 3 H), 4.42 (d, J=7.62 Hz, 2 H), 7.29 (dd, J=8.98, 1.95 Hz, 1 H), 7.45 (d, J=8.98 Hz, 2 H), 7.50 (d, J=1.76 Hz, 1 H), 7.70 (d, J=8.79 Hz, 2 H), 7.82 (d, J=8.98 Hz, 1 H), 8.31 (s, 1 H); MS (ESI) (M+H)⁺ 483.0; Anal. Calcd for C₂₆H₃₄N₄O₃S + 1.4 TFA + 0.5 H₂O: C, 53.11; H, 5.63; N, 8.60. Found: C, 53.02; H, 5.62; N, 8.71.

Example 9


***N*-(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)-2-pyrrolidin-1-ylacetamide**

5

STEP A:

2-Bromo-*N*-(4-{{[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)acetamide (42 mg, 0.0730 mmol) and pyrrolidine (0.030 mL, 0.365 mmol) were dissolved in 1 mL of DMF in a sealed tube. The solution was heated at 125°C in a Personal Chemistry SmithSynthesizer microwave instrument for 15 min. The solvent was concentrated. The residue was dissolved in EtOAc and was washed with saturated NaHCO₃ aqueous solution, brine and dried over anhydrous MgSO₄. The solvent was concentrated and the crude product was purified by reversed-phase HPLC using 20-80% CH₃CN/H₂O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 51 mg (88%); ¹H NMR (400 MHz, METHANOL-D₄) δ 1.24 (m, 5 H) 1.63 (m, 2 H) 1.67 (s, 11 H) 1.70 (m, 1 H) 1.78 (m, 2 H) 2.09 (m, 2 H) 2.17 (m, 2 H) 3.19 (m, 1 H) 3.27 (s, 3 H) 3.78 (m, 1 H) 4.27 (s, 2 H) 4.44 (d, J=7.62 Hz, 2 H) 7.28 (dd, J=8.98, 1.95 Hz, 1 H) 7.53 (d, J=8.98 Hz, 2 H) 7.59 (d, J=1.76 Hz, 1 H) 7.77 (d, J=8.98 Hz, 2 H) 7.82 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 566.2; Anal. Calcd for C₃₁H₄₃N₅O₃S + 2.7 TFA + 0.4 H₂O: C, 49.63; H, 5.32; N, 7.95. Found: C, 49.63; H, 5.33; N, 7.93.

25 **STEP B: 2-Bromo-*N*-(4-{{[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)acetamide**




4-Amino-N-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide (155 mg, 0.341 mmol) was dissolved in 5 mL of DCM containing a catalytic amount of DMAP. Bromoacetyl chloride (0.035 mL, 0.409 mmol) was added and the solution was stirred at rt for 3h. The solution was washed with saturated NaHCO_3 aqueous solution, brine and dried over anhydrous MgSO_4 . The crude product was purified by flash chromatography on silica gel using 50-75% EtOAc in hexanes as eluent to afford the title product. Yield: 175 mg (89%); ^1H NMR (400 MHz, CHLOROFORM-D) δ 1.09 (m, 1H) 1.12 (m, 1H) 1.15 (m, 1H) 1.19 (d J =8.59 Hz, 2H) 1.54 (s, 9H) 1.65 (m, 1H) 1.68 (m, 1H) 1.72 (m, 1H) 1.75 (m, 2H) 2.04 (m, 1H) 3.21 (d, J =1.17 Hz, 3H) 4.04 (s, 1H) 4.12 (m, 2H) 4.22 (s, 1H) 7.20 (m, 1H) 7.23 (m, 1H) 7.28 (m, 1H) 7.57 (m, 2H) 7.66 (t, J =8.49 Hz, 2H) 8.44 (d, J =8.40 Hz, 1H).

15

Example 10

*N*¹-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-*N*²,*N*²-dimethylglycinamide




20

Following the procedure for Example 9, using 2-bromo-*N*-(4-{[[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide (40 mg, 0.0695 mmol), dimethylamine hydrochloride (0.030 mg, 0.348 mmol) and DIPEA (0.060 mL, 0.348 mmol) in 1 mL of DMF. Yield: 35 mg (77%);

¹H NMR (400 MHz, METHANOL-D₄) δ 1.24 (m, 5 H) 1.64 (m, 2 H) 1.67 (s, 9 H) 1.70 (m, 1 H) 1.78 (m, 2 H) 2.10 (m, 1 H) 3.00 (s, 6 H) 3.27 (s, 3 H) 4.18 (s, 2 H) 4.45 (d, J=7.62 Hz, 2 H) 7.29 (dd, J=8.98, 1.95 Hz, 1 H) 7.54 (d, J=8.98 Hz, 2 H) 7.60 (d, J=1.76 Hz, 1 H) 7.77 (d, J=8.98 Hz, 2 H) 7.82 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 540.3; Anal. Calcd for C₂₉H₄₁N₅O₃S + 2.9 TFA + 0.5 H₂O: C, 47.53; H, 5.15; N, 7.96. Found: C, 47.57; H, 5.11; N, 7.99.

Example 11

10 *N*-(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)-2-morpholin-4-ylacetamide




Following the procedure for Example 9, using 2-bromo-*N*-(4-{{[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)

15 acetamide (56 mg, 0.0973 mmol) and morpholine (0.045 mL, 0.486 mmol) in 1 mL of DMF. Yield: 15mg (26%); ¹H NMR (400 MHz, METHANOL-D₄) δ 1.24 (m, 5 H) 1.64 (m, 2 H) 1.67 (s, 9 H) 1.70 (m, 1 H) 1.78 (m, 2 H) 2.11 (m, 1 H) 3.27 (s, 3 H) 3.42 (m, 4 H) 3.96 (m, 4 H) 4.17 (s, 2 H) 4.45 (d, J=7.62 Hz, 2 H) 7.29 (dd, J=8.98, 2.15 Hz, 1 H) 7.54 (d, J=9.18 Hz, 2 H) 7.60 (d, J=1.56 Hz, 1 H) 7.77 (d, J=8.98 Hz, 2 H) 7.83 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 582.2; Anal. Calcd for C₃₁H₄₃N₅O₄S + 3.2 TFA + 0.2 H₂O: C, 47.27; H, 4.94; N, 7.37. Found: C, 47.23; H, 4.92; N, 7.49.

Example 12


25 *N*¹-(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)glycinamide



Following the procedure for Example 9, using 2-bromo-N-(4-((2-tert-butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl)methyl)amino)sulfonyl)phenyl acetamide (37 mg, 0.0608 mmol) and ammonium hydroxide (28% aqueous) (0.5 mL, excess) in 1 mL of DMF. Yield: 28 mg (74%); ^1H NMR (400 MHz, METHANOL- D_4) δ 1.24 (m, 5 H), 1.64 (m, 2 H), 1.67 (s, 9 H), 1.70 (m, 1 H), 1.78 (m, 2 H), 2.10 (m, 1 H), 3.27 (s, 3 H), 3.89 (s, 2 H), 4.44 (d, $J=7.62$ Hz, 2 H), 7.30 (dd, $J=8.98, 1.95$ Hz, 1 H), 7.53 (d, $J=9.18$ Hz, 2 H), 7.58 (d, $J=1.76$ Hz, 1 H), 7.76 (d, $J=8.98$ Hz, 2 H), 7.82 (d, $J=9.18$ Hz, 1 H); MS (ESI) ($\text{M}+\text{H}$) $^+$ 512.0; Anal. Calcd for $\text{C}_{27}\text{H}_{37}\text{N}_5\text{O}_3\text{S} + 2.6 \text{ TFA} + 1.6 \text{ H}_2\text{O}$: C, 46.21; H, 5.15; N, 8.37. Found: C, 46.22; H, 5.09; N, 8.43.

Example 13


2-[(4-((2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl)methyl)amino)sulfonyl]phenyl]amino]-2-oxoethyl acetate



Following the procedure for Example 9, using 2-bromo-N-(4-((2-tert-butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl)methyl)amino)sulfonyl)phenyl acetamide (50 mg, 0.0869 mmol) and sodium acetate (35 mg, 0.434 mmol) in 2 mL of DMF. The product was used directly for the next step without any further purification. Yield: 48 mg (99%); MS (ESI) ($\text{M}+\text{H}$) $^+$ 555.2.

Example 14

***N*-(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide**




5 2-[(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)amino]-2-oxoethyl acetate (48 mg, 0.0869 mmol) was refluxed in 2 mL of EtOH containing 1M LiOH (0.5 mL, excess) for 2h. The solvent was concentrated and the residue was dissolved in EtOAc. The organic phase was washed with saturated NaHCO₃ aqueous solution, brine and dried over anhydrous

10 MgSO₄. The solvent was concentrated and the crude product was purified by reversed-phase HPLC using 20-80% CH₃CN/H₂O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 16 mg (29%); ¹H NMR (400 MHz, METHANOL-D₄) δ 1.24 (m, 5 H), 1.63 (m, 2 H), 1.67 (s, 9 H), 1.71 (m, 1 H), 1.78 (m, 2 H), 2.10 (m, 1 H), 3.27 (s, 3 H), 4.13 (s, 2 H), 4.45 (d, J=7.62 Hz, 2 H),

15 7.31 (dd, J=9.08, 2.05 Hz, 1 H), 7.49 (d, J=8.79 Hz, 2 H), 7.53 (d, J=1.95 Hz, 1 H), 7.83 (m, 3 H); MS (ESI) (M+H)⁺ 513.0.

What is claimed is:

1. A compound of formula I or a pharmaceutically acceptable salt thereof:



5

wherein

R^1 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{4-8} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, and C_{3-6} heterocycloalkyl, wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10}

10 $cycloalkyl-C_{1-4}$ alkyl, C_{4-8} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, and C_{3-6} heterocycloalkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6} alkylamino and di C_{1-6} alkylamino;

15 R^2 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, and C_{4-8} cycloalkenyl- C_{1-4} alkyl, wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, and C_{4-8} cycloalkenyl- C_{1-4} alkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6} alkylamino and di C_{1-6} alkylamino;

20 R^3 is selected from -H, C_{1-6} alkyl, C_{2-6} alkenyl, and C_{1-6} acyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{1-6} acyl used in defining R^3 is optionally substituted with one or more groups selected from $CH_3C(=O)-O-$, halogen, cyano, methoxy, ethoxy, hydroxy, amino, alkylamino, dialkylamino, and C_{3-6} heterocycloalkyl; and

25 R^4 is selected from -H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl.

2. A compound as claimed in claim 1, wherein

R^1 is selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl- C_{1-4} alkyl and C_{3-6} heterocycloalkyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl- C_{1-4} alkyl and C_{3-6} heterocycloalkyl- C_{1-4} alkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, hydroxy and amino;

5 R^2 is selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, and C_{4-6} cycloalkenyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, and C_{4-6} cycloalkenyl- C_{1-4} alkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy and hydroxy;

10 R^3 is selected from -H, C_{1-6} alkyl, C_{2-6} alkenyl, and C_{1-6} acyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{1-6} acyl used in defining R^3 is optionally substituted with one or more groups selected from $CH_3C(=O)-O-$, halogen, methoxy, ethoxy, hydroxy, amino, methylamino, dimethylamino, and C_{3-6} heterocycloalkyl; and

15 R^4 is selected from -H and C_{1-3} alkyl.

3. A compound as claimed in claim 1,

R^1 is selected from cyclopentyl-methyl, cyclohexyl-methyl, cyclobutyl-methyl, tetrahydropyranyl-methyl, tetrahydrofuranyl-methyl, morpholinyl-methyl, 20 piperdinylethyl, N-methyl-piperdinylmethyl, and piperdanyl-methyl;

R^2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl, isopentyl, 2-methoxy-2-propyl, 2-hydroxy-propyl, 1-methyl-propyl, 1,1-dimethyl-propyl, 1,1-dimethyl-3-buten-1-yl, ethyl, and 2-propyl;

R^3 is selected from -H, C_{1-6} alkyl, and C_{1-6} acyl, wherein said C_{1-6} alkyl, and C_{1-6} acyl used in defining R^3 is optionally substituted with one or more groups selected from $CH_3C(=O)-O-$, halogen, methoxy, hydroxy, amino, methylamino, dimethylamino, pyrrolidinyl, and morpholinyl; and

25 R^4 is selected from -H and methyl.

30 4. A compound as claimed in claim 1, wherein

R^1 is selected from cyclohexyl-methyl and tetrahydropyranyl-methyl;

R^2 is t-butyl;

R^3 is selected from -H, methyl, ethyl, propyl, 2-propyl, formyl, acetyl, ethylcarbonyl, 2-propylcarbonyl, t-butyloxycarbonyl, 2-amino-acetyl, 2-dimethylamino-acetyl, 2-acetyloxy-acetyl, 2-hydroxy-acetyl, 2-bromo-acetyl, 2-(morpholin-1-yl)-acetyl, and 2-(pyrrolindin-1-yl)-acetyl; and

5 R^4 is selected from -H and methyl.

5. A compound selected from:

10 N -(4-{{[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl) acetamide;

15 N -[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]- N -methyl-4-nitrobenzenesulfonamide;

20 4-Amino- N -[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]- N -methylbenzenesulfonamide;

25 N -(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)propanamide;

30 N -(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)-2-methylpropanamide;

N -(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)-2,2-dimethylpropanamide;

N -[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-(ethylamino)- N -methylbenzenesulfonamide;

N -[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-(formylamino)- N -methylbenzenesulfonamide;

N -(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)-2-pyrrolidin-1-ylacetamide;

N^1 -(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)- N^2 , N^2 -dimethylglycinamide;

N -(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)-2-morpholin-4-ylacetamide;

N^1 -(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)glycinamide;

 2-[(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)amino]-2-oxoethyl acetate;

101494-1

N-(4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl)phenyl)-2-hydroxyacetamide; and pharmaceutically acceptable salts thereof.

5 6. A compound according to any one of claims 1-5 for use as a medicament.

7. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the therapy of pain.


10 8. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the treatment of anxiety disorders.

9. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the treatment of cancer, multiple sclerosis, Parkinson's disease, 15 cancer, Huntington's chorea, Alzheimer's disease, gastrointestinal disorders and cardiavascular disorders.

10. A pharmaceutical composition comprising a compound according to any one of claims 1-5 and a pharmaceutically acceptable carrier.

20 11. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.


25 12. A method for preparing a compound of formula I,



I

comprising:

reacting a compound of formula II,

**II**

with a compound of R^2COX , in the presence of a base, such as an alkylamine, and optionally a coupling reagent, followed by treatment with an acid;

5 wherein

X is selected from Cl, Br, F and OH;

10 R^1 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{4-8} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, and C_{3-6} heterocycloalkyl, wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{4-8} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, and C_{3-6} heterocycloalkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6} alkylamino and di C_{1-6} alkylamino;

15 R^2 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, and C_{4-8} cycloalkenyl- C_{1-4} alkyl, wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, and C_{4-8} cycloalkenyl- C_{1-4} alkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6} alkylamino and di C_{1-6} alkylamino;


20 R^3 is selected from -H, C_{1-6} alkyl and C_{1-6} acyl optionally substituted with one or more groups selected from $CH_3C(=O)-O-$, halogen, cyano, methoxy, ethoxy, hydroxy, amino, alkylamino, dialkylamino, and C_{3-6} heterocycloalkyl; and

25 R^4 is selected from -H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl.

13. A compound of 2-Bromo-*N*-(4-{{[2-tert-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide.

ABSTRACT

Compounds of formula I or pharmaceutically acceptable salts thereof:



I

wherein R^1 , R^2 , R^3 , and R^4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

10

15

10
11
12
13
14
15
16
17
18
19
20